There has been a welcome growth in cross-disciplinary research integrating social, cultural and community engagement (SCCE) to positively have an impact on mental health. The advantages are both gains in enhancing well-being and improving mental health, and also potentially preventing the occurrence of mental illness in the first place. Community ‘assets’ can vary from active engagement such as participating in sports, community and voluntary groups, to more passive enjoyment of museums, nature and the local environment, and heritage sites. It is clear these are not ‘run’ by health and social care services, although there is an increased prominence in ‘social prescribing’. However, some observers have questioned if the field is necessarily focused upon the issues of greatest contemporary relevance and importance (or indeed if it is established what these are).

In an attempt to clarify the focus of SCCE, Fancourt et al engaged over a thousand key stakeholders in a six-phase design that aimed to integrate findings for a collective prioritisation of critical questions for SCCE research.1 Four major themes emerged: the mode, process, impact of engagement and infrastructure required to facilitate this. There is a need to better focus on intervention effectiveness and cost-effectiveness, and elucidation of the theory and mechanisms behind these. Breaking down barriers to collaboration, and ensuring sustainability are also considered key. The authors argue that this moves SCCE work from being a subset of other areas, to its own overarching topic with key research priorities. They note how there are an estimated million ‘assets’ in the UK, including over 40 000 choirs, 1300 theatres, 150 000 sports clubs and 300 000 voluntary associations and community groups. Something for everyone, we would think and a re-emphasis of the broader social determinants of health and well-being. They also highlight that the findings are particularly timely as we – hopefully – approach the end of the pandemic, yet – challengingly – will likely face enduring mental ill health sequelae for which wider non-medical interventions and activities will be crucial.

The end of a calendar year inevitably brings about cultural rankings of the best stuff in the past year, decade or century. And of course, they are mostly wrong (Abbey Road is not all that great, and Annie Hall is far from being the funniest film ever*). What were the most important statistical ideas in the past 50 years? Gelman & Vehtari present their opinions of these, starting from bootstrapping.2 Say you want to estimate the average height of a population but can only afford to obtain a sample of \( n = 100 \) random observations from the population and you have no idea about the underlying distribution of the population – so for example, you cannot assume a symmetric, normal, or ‘bell-shaped’ distribution. A summary statistic of the 100 observations might be the mean but this might not be reliable because the population distribution is not actually symmetric. With bootstrap resampling, we assume that our original \( n = 100 \) sample is representative of the population (whatever that might be) and put these 100 observations in a hypothetical bag. We randomly pick one observation from the bag, make a ‘copy’ for a new ‘fake’ sample and (this is important) replace the observation back in the bag. Repeating this 100 times, we have a new ‘fake’ population sample and we compute our summary statistic for this fake sample. Do this 1000 times, and then we can form a histogram of the 1000 fake sample means – if this histogram is narrow we have some reassurance that the mean is a useful representation for the underlying population of people’s heights. The same idea can be applied to inferential statistics (such as hypothesis tests) when we have small samples or cannot make assumptions about theoretical population distributions.

Another 50-year highlight from Gelman & Vehtari is overparameterised models and regularisation; that is, how can we fit models with vast numbers of parameters often exceeding the number of samples/observations while at the same time avoiding overfitting? This is the problem where a complex model exhibits so much flexibility it will fit anything, including random fluctuation or noise in the data, simultaneously failing to capture the underlying trend or pattern in the data. Regularisation methods offer to help in this situation and reduce overfitting by placing constraints on the model parameters or output of the model. This idea is vital in biosciences and medicine because of its applications in massive biological datasets, like neuroimaging and genomics where we generally have few samples (tens or hundreds) but a model requires thousands of parameters. And of course, current machine-learning techniques would not be possible at all without regularisation methods where a typical model has of the order millions of parameters and thousands (or tens of thousands) of observations.

One unifying theme in Gelman & Vehtari’s survey (also including Bayesian and robust inference, counterfactual causal inference, multilevel models, generic model estimation algorithms and decision analysis) is computation both as a tool (for example for data visualisation, crunching numbers quickly and accurately) and as an enabler – for example bootstrap procedures are wholly impractical without computers. Further, computer-enabled statistics has meant that almost anyone with a laptop can start analysing data and data-sets too large for any one person or machine to analyse (‘big data’) and these can now be processed and visualised en masse.

Oftentimes elucidation of biological processes can feel a world away from the deep pain and suffering we see in human experience. Voices calling for us to bridge the lab and the clinic for a better gestalt approach to treatment are growing ever louder1, but are often considered to be peddling a ‘nice to have’ rather than an essential to delivering quality care. An exciting, and controversial, older example of this potential bridge is the discussion of medications such as propranolol being used to disrupt memory consolidation after traumatic events. By understanding the way in which memories form, a precise interruption of the process could potentially prevent the anguish and disability that can come from resulting phobias or post-traumatic stress disorder. Although with memory being so central to our identities, growth and responsibility, not to mention the potential for abuse, this still sits firmly with bioethicists. However, a recent paper in Neurosypchospharmacology brings a new, perhaps less controversial, version of this idea from the world of stress.3 Within animal models, acute and chronic stress cause changes in dendritic architecture within the basolateral amygdala (BLA), unique from that seen in the hippocampus, which corresponds with an increase of anxiety-like behaviour after a delay of 10 days.

The authors explored the oral administration of corticosterone 24 h after a 2 h immobilisation stressor in rats on amygdalar dendritic plasticity and animal models of anxiety behaviour. Animals within the control group experienced an increase of endogenous corticosterone signalling, followed by a delayed reduction of exploratory behaviour in the elevated plus maze, reduced social

---

* These provocative musings of the second author in Kaleidoscope are clearly frankly wrong, and designed primarily to upset the sensibilities of the lead author. However, as the lead author controls the copy that goes to the journal, he herein highlights this egregious cultural error, and furthermore points out the limited musical talent of Tom Waits.
interaction and an increase in BLA spine density 10 days later. In the
treatment group, corticosterone administration appears to have
supplanted the natural surge of stress hormones and prevented
the development of detrimental impact seen at the cellular and
behavioural levels. Although not without its own philosophical ques-
tions, the use of acute trauma, and oral administration of treatment
24 h post-event, provides a clinically relevant model showing the
exciting potential to reverse the delayed impact of traumatic stress
by harnessing the somewhat counterintuitive protective effects of
gluocorticoids.

Which evolutionary changes underpin the unprecedented growth
of human brains in our ancestral lineage? Any adaptive changes
growing that calorie-hungry organ could only be supported once
ancient hominins had ready access to surplus energy – the
cooking of food appearing key but what were those changes? Two
processes are possible: alteration of protein sequences – ‘making new things’ with DNA; and differential gene expression –
changing the regulation of how existing proteins are expressed.
There is actually relatively little evidence for either. Regarding the
former, if one explores differences in intelligence between us and
other great apes, it does not seem as though we can link this to dif-
f erent neural proteins compared with those of our hominid cousins.
So attention turns to the latter, that we primarily express them dif-
ferently. Liu & Robinson-Rechavi describe a new method for the
historically difficult process of determining positive selection on
transcription factor binding sites – in other words the regulation
of expression – that did not require the detection of accelerated evo-
lution or a priori definition of nearby non-coding neutral sites. They
used this to compare positive selection at the binding site of CTCF, a
highly conserved transcriptional regulator, between human and
mouse cell types. Human cells related to brain function (but not
other human cell types) had the highest proportion of positive
selection, occurring on a genetic lineage that has occurred since divergence from chimpanzees. The findings support the
long-proposed, but until now less evidenced, hypothesis that it is
adaptive regulation and accelerated gene expression that underpin
our species unique brain growth.

N-acetylaspartylglutamate (NAAG) is a ubiquitous, but hitherto
ugly and understudied neurotransmitter that is co-released
with glutamate. It is a selective agonist for the metabotropic glu-
materic receptor mGluR3 found on astrocytes that facilitates glu-
matate re-uptake. Its roles have thus been linked with limiting
glutamate excitotoxicity and as part of a negative feedback loop
for glutamate signalling. More recent work has linked the
mGluR3 with working memory circuitry in the dorsolateral pre-
frontal cortex (DLPFC) of primates, the DLPFC being one of the
key evolutionary areas of brain growth in our own species. Zink
et al report on a fascinating, complex investigation of this. They
looked at the relationships between the expression of the genes
FOLH1 (coding for GCPPI, which regulates the amount of
NAAG in the synapse) and GRM3 (coding for the mGluR3). They
found that a missense mutation of FOLH1 was associated with
decreased NAAG, and that NAAG levels in the synapse were posi-
tively correlated with cognitive performance. Genetic variants of
FOLH1 are associated with IQ in the general population, and also
with cognitive impairment in schizophrenia; these data show how
this might occur. NAAG–mGluR signalling appears to have had
an important role across evolutionary time in the development of
human intelligence in our expanding DLPFC. Practically, this infor-
mation also offers the possibility of treatment: increasing NAAG via
FOLH1/GCPPI inhibition putatively might enhance cognitive
performance.

Finally, glycobiology is your new word this month. Glycosylation
is the highly regulated enzymatic modification of proteins
through the addition of sugars. These changes have important
complex effects for cells and ultimately our whole bodies; might
any abnormalities of such essential processes underpin any psycho-
pathology? Mealer et al discuss emerging findings from large-scale
genome-wide association studies in psychosis. They note that
one of the strongest coding variants in such studies is a missense
mutation in the manganese transporter SLC39A8, which is linked
with altered glycosylation. The finding holds true for variants of
several other genes that have been clearly linked with both schizo-
phrenia and encoding glycosylating enzymes. Adding to the link,
some critical proteins involved with the dopamine D2 receptor, glu-
tamate receptors, complement-associated proteins and voltage-
gated calcium channels require modification via glycosylation.
The roles for glycans in optimising functioning are varied and not
yet fully understood, but include cellular localisation and internal-
isation of receptors, and protein trafficking. The authors summarise
that it might be that pathological post-translational glycosylated
changes of some key proteins underpins much of the aetiology of
psychoses, at least in some cases across this heterogeneous spec-
trum. There is much work ahead to determine if and when this is
the case, and the precise (pathological) mechanisms through
which this might occur. However, their hypothesis certainly offers
potential downstream therapeutic targets.

References

1 Fancourt D, Bhui K, Chatterjee H, Crawford P, Crossick G, DeNora T, et al. Social, cultural and community engagement and mental health: cross-discipli-
inary, co-produced research agenda. BJPsych Open 2021; 7. e31–e6.


3 Chakraborty P, Datta S, McEwen BS, Chattarji S. Corticosterone after acute
stress prevents the delayed effects on the amygdala. Neuropsychopharmacol
2020; 45: 2139–46.

4 Liu J and Robinson-Rechavi M. Robust inference of positive selection on

5 Zink CF, Barker PB, Sawa A, Weinberger DR, Wang M, Quillan H, et al. Association of missense mutation in FOLH1 with decreased NAAD levels and
impaired working memory circuitry and cognition. Am J Psychiatry [Epub

6 Mealer RG, Williams SE, Daly MJ, Scolding NM, Cummings RG, Smoller JW. Glycobiology and schizophrenia: a biological hypothesis emerging from gen-